Net profit of Glenmark Life Sciences declined 33.08% to Rs 97.94 crore in the quarter ended March 2024 as against Rs 146.36 crore during the previous quarter ended March 2023. Sales declined 13.64% to Rs 536.60 crore in the quarter ended March 2024 as against Rs 621.32 crore during the previous quarter ended March 2023.For the full year,net profit rose 0.84% to Rs 470.89 crore in the year ended March 2024 as against Rs 466.96 crore during the previous year ended March 2023. Sales rose 5.64% to Rs 2283.21 crore in the year ended March 2024 as against Rs 2161.22 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales536.60621.32 -14 2283.212161.22 6 OPM %26.3633.22 -29.5329.72 - PBDT144.21209.15 -31 684.74670.70 2 PBT129.68197.63 -34 631.29628.61 0 NP97.94146.36 -33 470.89466.96 1 Powered by Capital Market - Live News

Glenmark Life Sciences announced that Gita Nayyar (DIN: 07128438), has tendered her resignation as a Non-Executive, Independent Director of the Company, with effect from 22 April 2024. Powered by Capital Market - Live News

Glenmark Life Sciences will hold a meeting of the Board of Directors of the Company on 25 April 2024.Powered by Capital Market - Live News

Net profit of Glenmark Life Sciences rose 13.13% to Rs 118.77 crore in the quarter ended December 2023 as against Rs 104.99 crore during the previous quarter ended December 2022. Sales rose 5.93% to Rs 572.80 crore in the quarter ended December 2023 as against Rs 540.73 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales572.80540.73 6 OPM %30.1326.90 - PBDT173.87151.90 14 PBT160.69141.14 14 NP118.77104.99 13 Powered by Capital Market - Live News

Glenmark Life Sciences (GLS) announced the signing of a Master Supply Agreement (MSA) with a Japanese innovator pharmaceutical company with global presence in Europe, United States and Asia. Under the aegis of the Master Supply Agreement, Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator. Glenmark Life Sciences will leverage its expertise in API manufacturing to support the global pharmaceutical innovator`s initiative in the field of urinary anti-spasmodic therapeutics. As part of this collaboration, product portfolios of various affiliates of the global innovator may also be added in the future. The API for the finished formulation will be supplied to all major regulated markets such as United States, Europe and Japan. The estimated commercial value of this project is expected to be around $5million. Powered by Capital Market - Live News